SOURCE: Global Equity Reporter

June 17, 2011 09:00 ET

Market Research on Provectus Pharmaceuticals, Inc. and PolyMedix, Inc. - The Right Prescription

BEIJING--(Marketwire - Jun 17, 2011) - Today, announced its research report highlighting Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) and PolyMedix, Inc. (OTCBB: PYMX). Full report download is available at

While it is thought that the recent health care reform legislation will negatively affect industry profitability over the next few years, new innovations within the healthcare field have maintained an influx of new interest to the industry. Combining medical technology with human touch, the healthcare industry diagnoses, treats, and administers care around the clock -- responding to the needs of millions of people. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology. Longer term, it is expected that a wider acceptance of biomarker research and genetic-targeted clinical studies to help limit expense. It is viewed that therapeutics for cancer and infectious diseases and autoimmune and inflammatory treatments are primary growth areas.

Global Equity is reporting on Provectus Pharmaceuticals, Inc. as a development-stage pharmaceutical company. The Company develops, licenses, markets and sells products in three sectors of the healthcare industry: over-the-counter products (OTC products), prescription drugs and medical device systems. Through discovery and use of scientific and medical technologies, it has developed a portfolio of technologies that support multiple products in the prescription drug, medical device and OTC products categories. The full report and profile on Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) is available here:

Global Equity Reporter brings PolyMedix, Inc. to the table as a biotechnology company focused on treating acute cardiovascular disorders and life threatening, serious, infectious diseases with small synthetic molecule compounds that mimic the activity of large natural protein molecules, compounds referred to as biomimetics. It has created heparin antagonist compounds (heptagonists), defensin mimetic antibiotic compounds and other drug compounds intended for human therapeutic use. The full report and profile on PolyMedix, Inc. (OTCBB: PYMX) is available here:

About Global Equity Reporter
Global Equity Reporter is a premier source for microcap research -- providing a wide range of due diligence and investment insight on stocks all over the market Global Equity Reporter's primary focus is to alert our valued subscribers to small cap and microcap companies poised for explosive movement in the market. As every investor knows, timing in the market is critical, and that's where Global Equity Reporter delivers.

Contact Information